David Rosenbloom compensation by year
BAXTER INTERNATIONAL Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $760,000 |
| Bonus | $0 |
| Stock awards | $1,989,036 |
| Option awards | $627,345 |
| Non-equity incentive | $348,840 |
| Pension and deferred compensation | $0 |
| All other | $68,943 |
| Total | $3,794,164 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BAXTER INTERNATIONAL INC DEF 14A filed March 23, 2026, accession 0001628280-26-020330, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 37,182 | $710,539 | — |
| RSU | 17,884 | $341,760 | — |
| RSU | 17,883 | $341,750 | — |
| RSU | 17,047 | $325,776 | — |
| RSU | 4,956 | $94,713 | — |
| Option | 58,873 | — | $35.44 |
| Option | 33,442 | — | $74.47 |
| Option | 19,190 | — | $39.06 |
Per the Outstanding Equity Awards at Fiscal Year-End table in BAXTER INTERNATIONAL INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
BAXTER INTERNATIONAL’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Andrew Hider | President and CEO | $29,805,182 |
| Joel Grade | Former Executive Vice President and CFO | $8,209,568 |
| Jos Almeida | Former Chair of the Board, President and CEO | $7,666,044 |
| Heather Knight | Former Executive Vice President, COO and Interim Group President, Medical Products & Therapies | $6,074,548 |
| Reazur Rasal | Executive Vice President and Group President, Healthcare Systems & Technologies | $5,246,214 |
| Reazur Rasul | Executive Vice President and Group President, Healthcare Systems & Technologies | $5,246,214 |
| Alok Sonig | Former Executive Vice President and Group President, Pharmaceuticals | $5,239,273 |
| Brent Shafer | Non-Executive Chair and Former Executive Chair and Interim CEO | $3,809,993 |
| David Rosenbloom · this page | Executive Vice President and General Counsel | $3,794,164 |
| Maria Soriano | Group President, Infusion Therapies & Technologies and Pharmaceuticals | $2,654,841 |
The full BAXTER INTERNATIONAL compensation record
free company briefThis page is one person within BAXTER INTERNATIONAL's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order BAXTER INTERNATIONAL's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BAXTER INTERNATIONAL's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat